@article {4168,
	title = {Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats},
	journal = {American Journal of Physiology-Endocrinology and Metabolism},
	volume = {272},
	number = {1},
	year = {1997},
	note = {ISI Document Delivery No.: WG568Times Cited: 14Cited Reference Count: 39},
	month = {Jan},
	pages = {E30-E35},
	type = {Article},
	abstract = {In association with the insulin-mimetic properties, vanadium and related compounds have been shown to normalize hyperphagia associated with diabetes mellitus. The objective of this study was to clarify the effects of an organic vanadium compound, bis(maltolato)oxovanadium(IV) (BMOV), vs. food restriction on the metabolic abnormalities that occur in diabetes. BMOV was administered daily in drinking water to streptozotocin (STZ)-diabetic rats for 6 wk. Pair-fed groups were fed based on the intake for their respective counterparts from the previous day. Plasma parameters mere measured weekly after a carefully controlled 5-h fasting period. BMOV reduced plasma glucose (diabetic = 31.2 +/- 1.9, diabetic treated = 10.2 +/- 1.8, and diabetic pair fed = 34.2 +/- 1.1 mM), triglyceride, and cholesterol levels to normal without a concomitant increase in plasma insulin levels. There was no body weight gain in the diabetic pair-fed group compared with all other groups. BMOV but not pair feeding was effective in preventing the decreased cardiac function observed in STZ-diabetic rats. These data suggest that the glucose-lowering properties of BMOV are independent of the effects of dietary restriction and reinforce the efficacy of BMOV as an effective antihyperglycemic agent.},
	keywords = {diabetes, FA/FA, GLUCOSE-HOMEOSTASIS, glucose-lowering effect, HYPERINSULINEMIA, IN-VIVO, INSULIN SENSITIVITY, LONG-TERM IMPROVEMENT, MELLITUS, ORAL VANADATE, RATS, SPONTANEOUSLY HYPERTENSIVE RATS, STREPTOZOTOCIN, SULFATE, VANADYL},
	isbn = {0193-1849},
	url = {<Go to ISI>://A1997WG56800005},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
@article {2941,
	title = {IMPROVEMENT IN CARDIAC DYSFUNCTION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS FOLLOWING CHRONIC ORAL-ADMINISTRATION OF BIS(MALTOLATO)OXOVANADIUM(IV)},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {71},
	number = {3-4},
	year = {1993},
	note = {ISI Document Delivery No.: LN775Times Cited: 70Cited Reference Count: 40},
	month = {Mar-Apr},
	pages = {270-276},
	type = {Article},
	abstract = {Decreased cardiac function in streptozotocin-diabetic rats has been used as a model of diabetes-induced cardiomyopathy, which is a secondary complication in diabetic patients. The present study was designed to evaluate the therapeutic effect of a new organic vanadium complex, bis(maltolato)oxovanadium(IV), (BMOV), in improving heart function in streptozotocin-diabetic rats. There were four groups of male, Wistar rats: control (C), control treated (CT), diabetic (D), and diabetic treated (DT). Treatment consisted of BMOV, 0.5 mg/mL (1.8 mM) for the first 3 weeks and 0.75 mg/mL (2.4 mM) for the next 22 weeks, in the drinking water of rats allowed ad libitum access to food and water. BMOV lowered blood glucose to < 9 mM in 70\% of DT animals without any increase in plasma insulin levels, and mean blood glucose and plasma lipid levels were significantly lower in DT vs. D rats. Tissue vanadium levels were measured in plasma, bone, kidney, liver, muscle, and fat of BMOV-treated rats. Plasma vanadium levels averaged 0.84 +/- 0.07 mug/mL (16.8 muM) in CT rats and 0.76 +/-0.05 mug/mL (15.2 muM) in DT animals. The highest vanadium levels at termination of this chronic feeding study were in bone, 18.3 +/- 3.0 mug/g (0.37 mumol/g) in CT and 26.4 +/- 2.6 mug/g (0.53 mumol/g) in DT rats, with intermediate levels in kidney and liver, and low, but detectable levels in muscle and fat. There were no deaths in either the CT or DT group, and no overt signs of vanadium toxicity were present. Tissue vanadium levels were not correlated with die glucose-lowering effect. Isolated working heart parameters of left ventricular developed pressure (LVDP) and rate of pressure development (+dP/dT, and -dP/dT) indicated that BMOV treatment resulted in significant correction of the heart dysfunction associated with streptozotocin-induced diabetes in rat.},
	keywords = {ACTIVATION, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, diabetes, GLUCOSE-HOMEOSTASIS, INSULIN, MYOCARDIAL DYSFUNCTION, STREPTOZOTOCIN, SULFATE, VANADATE TREATMENT, VANADIUM},
	isbn = {0008-4212},
	url = {<Go to ISI>://A1993LN77500014},
	author = {Yuen, V. G. and Orvig, Chris and Thompson, K. H. and McNeill, J. H.}
}
